A new study suggests that people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) may live longer ...

A new study reveals that heart attack survivors could greatly reduce their risk of a second event by starting combination ...

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

A JAMA Internal Medicine study published April 7 examined the effects of changing the default prescription lengths for ...

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk ...

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk ...

Lowering cholesterol triggers other health problems. Mostly false. Prior to the introduction of statins four decades ago, ...

Recent research, presented at a major meeting of the Endocrine Society in Chicago, shows that bempedoic acid can lower LDL ...

A new study found that adding a second drug early after a heart attack may save lives. Those who added ezetimibe to a statin ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

One in four patients who present with elevated low-density lipoprotein cholesterol levels have no documented use of statin therapy, according to a study published April 16 in Epic Research.  Here are ...